Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.33 |
| ▸ | PNP | P00491 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29394441 | 1.00 | ADORA3 (0.33) | ADORA3ADORA2AADORA2BADORA1PNP | |
| SCHEMBL4907123 | 0.83 | PDPK1 (0.44) | — | |
| Water SCHEMBL8757461 | 0.81 | PDPK1 (0.42) | — | |
| Uric Acid SCHEMBL3325279 | 0.77 | — | — | |
| SCHEMBL27734016 | 0.72 | ADORA3 (0.35) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL29454410 | 0.71 | ADORA2A (0.61) | ADORA2AADORA1 | |
| SCHEMBL42335 | 0.71 | ADORA2A (0.61) | ADORA2AADORA1 | |
| SCHEMBL6481197 | 0.70 | NUDT1 (0.35) | PNP | |
| SCHEMBL29157618 | 0.68 | PI4KA (0.37) | — | |
| SCHEMBL8048768 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 869 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4681774-A2 | KHK INHIBITORS | Gilead Sciences, Inc. (US) | 2026-01-21 | — | — | EP | claimed |
| EP-4313967-B1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2025-11-12 | — | — | EP | claimed |
| EP-4313967-A1 | KHK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2024-02-07 | — | — | EP | claimed |
| US-20230416361-A1 | ENGINEERED CD200R ANTIBODIES AND USES THEREOF | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2023-12-28 | — | — | US | claimed |
| CN-117120429-A | KHK inhibitor | 吉利德科学公司 | 2023-11-24 | — | — | CN | claimed |
| WO-2023196866-A1 | ENGINEERED CD200R ANTIBODIES AND USES THEREOF | MIROBIO LIMITED (GB) | 2023-10-12 | — | — | WO | claimed |
| US-20230079863-A1 | KHK INHIBITORS | GILEAD SCIENCES, INC. | 2023-03-16 | — | — | US | claimed |
| WO-2022212194-A1 | KHK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2022-10-06 | — | — | WO | claimed |
| EP-3519558-A1 | USE OF ENGINEERED RENAL TISSUES IN ASSAYS | Organovo, Inc. (US) | 2019-08-07 | — | — | EP | claimed |
| WO-2018064323-A1 | USE OF ENGINEERED RENAL TISSUES IN ASSAYS | ORGANOVO, INC. (US) | 2018-04-05 | — | — | WO | claimed |
| WO-2009127230-A1 | MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION | CUREVAC GMBH (DE) | 2009-10-22 | — | — | WO | claimed |
| JP-3065650-A | — | — | None | — | — | JP | disclosed |
| US-12622876-B2 | Methods of suppressing delivery of exosomes to liver and spleen | LONZA SALES AG (CH) | 2026-05-12 | — | — | US | disclosed |
| US-20260092053-A1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4705318-A2 | KIDNEY-TARGETING AAV CAPSIDS AND METHODS OF USE THEREOF | Oregon Health & Science University (US) | 2026-03-11 | — | — | EP | disclosed |
| JP-H0365650-A | METHOD OF MEASURING DIHYDROXYADENINE | FUJIREBIO INC | 1991-03-20 | — | — | JP | disclosed |
| EP-0034038-B1 | USE OF SILVER HALIDE DEVELOPMENT ACCELERATORS, PHOTOGRAPHIC FILMS AND PROCESSES FOR DEVELOPING LITHOGRAFIC FILM | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-05-30 | — | — | EP | disclosed |
| US-4292391-A | PYRAZOLO/3,4-D/PYRIMIDINES; PHOTOLITHOGRAPHY | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-09-29 | — | — | US | disclosed |
| EP-0034038-A1 | Use of silver halide development accelerators, photographic films and processes for developing lithografic film | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-08-19 | — | — | EP | disclosed |
| JP-H00365650-A | — | — | 0001-01-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092053-A1 | KHK INHIBITORS | KHK, SLC5A2, HK1 | ADORA3 3619/4885ADORA2A 3124/4885ADORA2B 2845/4885 |
| US-20230079863-A1 | KHK INHIBITORS | KHK, KHDRBS1, NADK | ADORA3 4579/4885ADORA2A 4220/4885ADORA2B 4411/4885 |
| US-12622876-B2 | Methods of suppressing delivery of exosomes to liver and spleen | EXOSC10, EXOSC5, EXOSC4 | ADORA3 2468/4885ADORA2A 1799/4885ADORA2B 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.